Jordi A Matías-Guiu1, Vanesa Pytel2, María Nieves Cabrera-Martín3, Lucía Galán2, María Valles-Salgado2, Antonio Guerrero2, Teresa Moreno-Ramos2, Jorge Matías-Guiu2, José Luis Carreras3. 1. Department of Neurology, Hospital Clínico San Carlos, San Carlos Institute for Health Research (IdISSC), Universidad Complutense de Madrid, C/ Profesor Martín Lagos, s/n, 28040, Madrid, Spain. jordimatiasguiu@hotmail.com. 2. Department of Neurology, Hospital Clínico San Carlos, San Carlos Institute for Health Research (IdISSC), Universidad Complutense de Madrid, C/ Profesor Martín Lagos, s/n, 28040, Madrid, Spain. 3. Department of Nuclear Medicine, Hospital Clínico San Carlos, San Carlos Institute for Health Research (IdISSC), Universidad Complutense de Madrid, C/ Profesor Martín Lagos, s/n, 28040, Madrid, Spain.
Abstract
PURPOSE: We aimed to study brain metabolism and presence of beta-amyloid deposits using positron emission tomography (PET) in patients with amyotrophic lateral sclerosis (ALS). METHODS: This prospective cross-sectional study included 18 patients with definite or probable ALS according to the revised El Escorial diagnostic criteria, and 24 healthy controls. Patients underwent neurological and neuropsychological assessments, PET with (18)F-fluorodeoxyglucose (FDG), and amyloid-PET with (18)F-florbetaben. RESULTS: Patients with ALS showed hypometabolism in the frontal area and hypermetabolism in the cerebellum compared to healthy controls. Four patients (22 %) displayed cognitive impairment and decreased metabolism in the frontal area extending bilaterally to the parietal regions, and increased metabolism in the posterior area of the cerebellum. In patients with no cognitive impairment, metabolism was lower in the left superior frontal gyrus and higher in the anterior and posterior lobes of the cerebellum. In the individual analysis, six patients (35 %) displayed more anterior involvement with hypometabolism affecting the superior frontal, medial, and inferior gyri; six patients (35 %) exhibited a more posterior pattern with hypometabolism in the precentral and postcentral gyri and in the superior and inferior parietal lobules; two patients (11 %) showed a mixed pattern; and three patients (17 %) showed no alterations in brain metabolism. Three (16 %) showed increased (18)F-florbetaben uptake compared to controls. CONCLUSIONS: We have identified two main patterns of brain metabolism with an association to cognitive status. Only a subgroup of patients showed an increased uptake of the amyloid tracer. Our results suggest that ALS is heterogeneous from a clinical, metabolic, and molecular standpoint.
PURPOSE: We aimed to study brain metabolism and presence of beta-amyloid deposits using positron emission tomography (PET) in patients with amyotrophic lateral sclerosis (ALS). METHODS: This prospective cross-sectional study included 18 patients with definite or probable ALS according to the revised El Escorial diagnostic criteria, and 24 healthy controls. Patients underwent neurological and neuropsychological assessments, PET with (18)F-fluorodeoxyglucose (FDG), and amyloid-PET with (18)F-florbetaben. RESULTS:Patients with ALS showed hypometabolism in the frontal area and hypermetabolism in the cerebellum compared to healthy controls. Four patients (22 %) displayed cognitive impairment and decreased metabolism in the frontal area extending bilaterally to the parietal regions, and increased metabolism in the posterior area of the cerebellum. In patients with no cognitive impairment, metabolism was lower in the left superior frontal gyrus and higher in the anterior and posterior lobes of the cerebellum. In the individual analysis, six patients (35 %) displayed more anterior involvement with hypometabolism affecting the superior frontal, medial, and inferior gyri; six patients (35 %) exhibited a more posterior pattern with hypometabolism in the precentral and postcentral gyri and in the superior and inferior parietal lobules; two patients (11 %) showed a mixed pattern; and three patients (17 %) showed no alterations in brain metabolism. Three (16 %) showed increased (18)F-florbetaben uptake compared to controls. CONCLUSIONS: We have identified two main patterns of brain metabolism with an association to cognitive status. Only a subgroup of patients showed an increased uptake of the amyloid tracer. Our results suggest that ALS is heterogeneous from a clinical, metabolic, and molecular standpoint.
Authors: Michael C Riedel; Kimberly L Ray; Anthony S Dick; Matthew T Sutherland; Zachary Hernandez; P Mickle Fox; Simon B Eickhoff; Peter T Fox; Angela R Laird Journal: Neuroimage Date: 2015-05-19 Impact factor: 6.556
Authors: R Migliorelli; A Tesón; L Sabe; G Petracca; M Petracchi; R Leiguarda; S E Starkstein Journal: J Neuropsychiatry Clin Neurosci Date: 1995 Impact factor: 2.198
Authors: Jennifer L Whitwell; Stephen D Weigand; Bradley F Boeve; Matthew L Senjem; Jeffrey L Gunter; Mariely DeJesus-Hernandez; Nicola J Rutherford; Matthew Baker; David S Knopman; Zbigniew K Wszolek; Joseph E Parisi; Dennis W Dickson; Ronald C Petersen; Rosa Rademakers; Clifford R Jack; Keith A Josephs Journal: Brain Date: 2012-03 Impact factor: 13.501
Authors: Juergen Dukart; Robert Perneczky; Stefan Förster; Henryk Barthel; Janine Diehl-Schmid; Bogdan Draganski; Hellmuth Obrig; Emiliano Santarnecchi; Alexander Drzezga; Andreas Fellgiebel; Richard Frackowiak; Alexander Kurz; Karsten Müller; Osama Sabri; Matthias L Schroeter; Igor Yakushev Journal: PLoS One Date: 2013-02-25 Impact factor: 3.240
Authors: Jordi A Matías-Guiu; Carmen Guerrero-Márquez; María Nieves Cabrera-Martín; Ulises Gómez-Pinedo; María Romeral; Diego Mayo; Jesús Porta-Etessam; Teresa Moreno-Ramos; José Luis Carreras; Jorge Matías-Guiu Journal: Prion Date: 2017-05-16 Impact factor: 3.931
Authors: Stefanie M A Willekens; Donatienne Van Weehaeghe; Philip Van Damme; Koen Van Laere Journal: Eur J Nucl Med Mol Imaging Date: 2016-12-08 Impact factor: 9.236
Authors: Ulises Gómez-Pinedo; Rocio N Villar-Quiles; Lucia Galán; Jordi A Matías-Guiu; Maria S Benito-Martin; Antonio Guerrero-Sola; Teresa Moreno-Ramos; Jorge Matías-Guiu Journal: Front Neurol Date: 2016-11-08 Impact factor: 4.003